AGN-1135 (also known as racemic rasagiline or as N-propargyl-1-aminoindane) is a monoamine oxidase inhibitor (MAOI) that was never marketed.[1][2] It is the racemic form of rasagiline and is a mixture of the R(+)-enantiomer (rasagiline; TVP-1012) and S(–)-enantiomer (TVP-1022).[1][2] Like rasagiline, AGN-1135 is a selective monoamine oxidase B (MAO-B) inhibitor.[1] Virtually all of the MAOI activity of AGN-1135 lies in rasagiline, which is several orders of magnitude more potent as an MAO-B inhibitor than the S(–)-enantiomer.[1] In relation to this, enantiopure rasagiline was developed and marketed for use as a pharmaceutical drug rather than AGP-1135.[1]

AGN-1135
Clinical data
Other namesAGN-1135; Racemic rasagiline; (±)-Rasagiline; (RS)-Rasagiline; N-Propargyl-1-aminoindane
Identifiers
  • N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H13N
Molar mass171.243 g·mol−1
3D model (JSmol)
  • C#CCNC1CCC2=CC=CC=C12
  • InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2
  • Key:RUOKEQAAGRXIBM-UHFFFAOYSA-N

See also

edit

References

edit
  1. ^ a b c d e Finberg JP (February 2020). "The discovery and development of rasagiline as a new anti-Parkinson medication". Journal of Neural Transmission. 127 (2): 125–130. doi:10.1007/s00702-020-02142-w. PMID 31974721.
  2. ^ a b Chen JJ, Swope DM (August 2005). "Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease". Journal of Clinical Pharmacology. 45 (8): 878–894. doi:10.1177/0091270005277935. PMID 16027398. S2CID 24350277. Archived from the original on 11 July 2012.